Research Use Only. This article is a literature summary for laboratory research use only. Nothing on this page is medical advice or an instruction for human or animal use.
Abstract
This review summarises peer-reviewed literature on Retatrutide, with a focus on body-weight trial outcomes. It describes receptor pharmacology, preclinical findings and outcomes reported in published randomised controlled trials, and notes limitations of the current evidence. It does not provide dosing, administration or preparation information.
Background
Retatrutide (LY3437943) is an investigational single-peptide agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors, developed by Eli Lilly and Company. It is not authorised as a medicine by the MHRA, EMA or FDA and remains under clinical investigation.[1,2]
Mechanism of action
In preclinical characterisation, retatrutide showed agonism at human GIP and GLP-1 receptors with comparatively greater relative potency at GIPR, and additional glucagon-receptor (GCGR) agonism. Glucagon-receptor engagement is hypothesised to contribute increased energy expenditure and hepatic lipid oxidation, complementing incretin-mediated effects on insulin secretion and central appetite signalling observed in rodent models.[1,3]
Summary of published research
Retatrutide – Published clinical trial outcomes: body weight
In a 48-week phase 2 randomised, placebo-controlled trial in adults with obesity, retatrutide produced dose-dependent reductions in body weight from baseline, with a mean change of up to −24.2% in the highest-dose group compared with −2.1% with placebo.[4,5]
A phase 3 trial (TRIUMPH-2) in adults with obesity and type 2 diabetes has since been reported in The Lancet; readers should consult the primary publication for endpoints and results.[4,5]
Limitations of the evidence
Most clinical data come from industry-sponsored trials of defined pharmaceutical formulations under medical supervision; results cannot be extrapolated to research-grade material, which is not manufactured to medicinal GMP standards. Trial populations, durations and comparators differ, so cross-trial comparisons should be interpreted cautiously. Longer-term safety data for newer agents remain limited.
Conclusion
The published literature characterises these peptides as potent incretin-pathway receptor agonists with substantial bodies of preclinical and clinical-trial data. For laboratory work, researchers should rely on primary publications and verified analytical documentation for any material used.
References
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022; 34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013 PMID: 35985340.
- Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022; 400(10366):1869-1881. doi:10.1016/S0140-6736(22)02033-5 PMID: 36354040.
- Drucker DJ et al. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018; 27(4):740-756. doi:10.1016/j.cmet.2018.03.001 PMID: 29617641.
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023; 389(6):514-526. doi:10.1056/NEJMoa2301972 PMID: 37366315.
- Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026; 408(10563):1455-1472. doi:10.1016/S0140-6736(26)01861-1 PMID: 42810372.
Disclaimer: This article is for laboratory research use only. Not for human or veterinary use, not for consumption, and not intended to diagnose, treat, cure or prevent any disease. This page is an educational literature summary and is not medical advice.
